Skip to Main Content
Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite unusually blustery winds whipping through the Pharmalot campus. A quick peek out the nearby portal offers an interesting view of a few fallen tree branches nearby, a gazillion acorns, and some detritus along the street, too. But things will calm down soon enough. So why not join us for a cup of stimulation or three? We are favoring coconut this morning, for no particular reason. Meanwhile, here are a few items of interest to help you along. Hope you conquer the world today and, as always, do keep in touch …

Two drug makers and the nation’s three largest distributors are offering $22 billion in cash as well as medicines and services they value at $28 billion to resolve lawsuits alleging the industry fueled the U.S. opioid crisis, Reuters reports. McKesson (MCK), Cardinal Health (CAH), and AmerisourceBergen (ABC) offered to pay $18 billion in cash over 18 years, while Johnson & Johnson (JNJ) would pay $4 billion in cash, and Teva Pharmaceutical (TEVA) offered to give away medicines it values at $15 billion and provide distribution services valued in the billions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.